James F Howard
Dados Biográficos
| ID | 7143752 |
|---|---|
| NOME | James F Howard |
| PRENOMES | James F |
| SOBRENOME | Howard |
| ASSINATURA | HOWARD J F |
| AFILIAÇÕES | University of North Carolina at Chapel Hill |
| ORCID | 0000-0002-7136-8617 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 3 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 3 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2019 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2025 |
| ÍNDICE H | 0 |
Characterizing Guillain-Barré Risk Factors Among Traditional Medicare Beneficiaries
Guillain-Barré Syndrome (GBS) is a rare and potentially life-threatening autoimmune disorder affecting the peripheral nerves. We sought to identify demographic and clinical characteristics associated with GBS onset. In this retrospective case-control study, we used national 2005 to 2020 fee-for-service Medicare claims data to identify beneficiaries with incident GBS using a chart-validated algorithm (N = 16 280), matched 1:1 with non-GBS controls…
The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges
Objective: Better understanding the impact of social determinants of health (SDOH) barriers from the patient perspective is crucial to improve holistic patient support in generalized myasthenia gravis (gMG), a rare autoimmune disorder with high disease and treatment burden. The objective of this study was to identify economic challenges experienced by individuals living with gMG and SDOH barriers to better address current unmet needs. Methods: Ad…
Eculizumab improves fatigue in refractory generalized myasthenia gravis
Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624
Sem obras proeminentes nesta página.
Eculizumab improves fatigue in refractory generalized myasthenia gravis
Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624
The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges
Objective: Better understanding the impact of social determinants of health (SDOH) barriers from the patient perspective is crucial to improve holistic patient support in generalized myasthenia gravis (gMG), a rare autoimmune disorder with high disease and treatment burden. The objective of this study was to identify economic challenges experienced by individuals living with gMG and SDOH barriers to better address current unmet needs. Methods: Ad…
Characterizing Guillain-Barré Risk Factors Among Traditional Medicare Beneficiaries
Guillain-Barré Syndrome (GBS) is a rare and potentially life-threatening autoimmune disorder affecting the peripheral nerves. We sought to identify demographic and clinical characteristics associated with GBS onset. In this retrospective case-control study, we used national 2005 to 2020 fee-for-service Medicare claims data to identify beneficiaries with incident GBS using a chart-validated algorithm (N = 16 280), matched 1:1 with non-GBS controls…
Medicine (2 obras) · Myasthenia Gravis and Thymoma (2 obras) · Peripheral Neuropathies and Disorders (2 obras) · Public health (2 obras) · Adrenal Hormones and Disorders (1 obras) · Antibody (1 obras) · Autoimmune Neurological Disorders and Treatments (1 obras) · Business (1 obras) · Coagulation, Bradykinin, Polyphosphates, and Angioedema (1 obras) · Complement system (1 obras)